RT Journal Article
SR Electronic
T1 Continuity of services for patients with tuberculosis in China in the COVID-19 era
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.16.20150292
DO 10.1101/2020.07.16.20150292
A1 Shen, Xin
A1 Sha, Wei
A1 Yang, Chongguang
A1 Pan, Qichao
A1 Cohen, Ted
A1 Cheng, Shiming
A1 Cai, Qingshan
A1 Kan, Xiaohong
A1 Zong, Peilan
A1 Zeng, Zhong
A1 Tan, Shouyong
A1 Liang, Ruixia
A1 Bai, Liqiong
A1 Xia, Jia’an
A1 Wu, Shucai
A1 Sun, Peng
A1 Wu, Guihui
A1 Cai, Cui
A1 Wang, Xiaolin
A1 Ai, Kaixing
A1 Liu, Jianjun
A1 Yuan, Zheng’an
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.16.20150292.abstract
AB It is crucial to maintain continuity of essential services for people affected by tuberculosis (TB). Efforts to deliver these essential services in many global settings have been complicated by the emergence and global spread of SARS-CoV-2 and the pandemic of COVID-19. Understanding how the COVID-19 pandemic has impacted the availability of TB diagnostic and treatment services is critical for identifying policies that can mitigate disruptions of these essential services. China has a dual burden of TB and COVID-19. We conducted a survey and collected data from 13 provinces in China to evaluate the early impact of COVID-19 on TB services and to document interventions that were adopted to maintain the continuity services for TB patients during the pandemic. We use these data to identify additional opportunities which will improve the ability of TB programs to maintain essential services during this crisis. While health systems and underlying epidemiology differ between countries, we believe that sharing China’s experience can inform the design of locally tailored strategies to maintain essential TB services during the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received funding from the Chinese National Science and Technology Major Projects (grant 2018ZX10715012 to XS and ZY), and the Natural Science Foundation of China (grant 81872679 to XS and QP). CY received funding from the Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award. All the funding sources had no role in the preparation of this report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Shanghai Municipal Center for Disease Control and Prevention.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available upon request.